Doramapimod (BIRB 796)

For research use only. Not for use in humans.

目录号:S1574 中文名称:达马莫德

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2403.35 现货
RMB 1221.86 现货
RMB 2215.96 现货
RMB 3866.11 现货
RMB 12039.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Doramapimod (BIRB 796)发表文献85篇:

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述 Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。
特性 BIRB 796是第一个进入三期临床试验的p38 MAPK抑制剂。
靶点
JNK2 [1]
()
c-RAF [1]
()
Fyn [1]
()
p38α [1]
(Cell-free assay)
p38α [7]
()
0.1 nM(Kd) 38 nM
体外研究

BIRB 796作用于ERK-1,SYK,IKK2β,ZAP-70,EGFR激酶,HER2,蛋白激酶 A(PKA),PKC,PKC-α,PKC-β(I和II)和PKC-γ没有明显抑制效果。BIRB 796通过在吗啉氧和p38α的ATP结合域间形成氢键,显著提高亲和力。BIRB 796是作用于人类p38 MAPK的最有效和分离最慢的抑制剂之一。[1] BIRB 796 有效抑制c-Raf-1和Jnk2α2,IC50分别为1.4和0.1 nM。[2] 高浓度BIRB796也抑制SAPK3/p38γ的活性和激活。BIRB796阻断压力诱导的框架蛋白SAP97磷酸化, SAP97是SAPK3/p38γ的底物。BIRB796作用于HEK293细胞,阻断JNK1/2激活和活性,而作用于Hela细胞,不抑制ERK1/ERK2激活和活性。而且, BIRB796与p38 MAPKs或JNK1/2的结合,降低上游激酶MKK6或MKK4磷酸化,而不增强去磷酸化。 [3] BIRB 796 作用于TNF-α和TGF-β1引起的BMSCs,下调IL-6和VEGF分泌。[4] BIRB-796有吡唑环 ,使亲脂的末端异丁基基团 与低选择性位点结合,甲苯基环与高选择性位点结合。BIRB-796也抑制B-Raf和Abl,IC50分别为83 nM 和14.6 μM。 [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-92 NVHPTIE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\adJpKSzVyPUK0MlM5OzhizszN M37KU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H2228 NFr4eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy3V2xMUUN3ME2yN{43PjZ6IN88US=> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
CAPAN-1 Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ{LkG4PFQh|ryP NG\Fb|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
SK-MEL-1 M33OVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1OIxpUUN3ME2yNE4{Pjh|IN88US=> NGTRXIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
DB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q2eGlEPTB;MUiuO|kzOyEQvF2= NEKxUmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
AN3-CA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHZSVhYUUN3ME2xPE4yKM7:TR?= NVXpN5FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
EW-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF5Lkm1NVYh|ryP MnP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
LC-2-ad MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zUWmlEPTB;MUeuOFM3PiEQvF2= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
ES8 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDvZ4xTUUN3ME2xO{4yPjdizszN NH7RbGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H1581 NIi2XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF5LkC0OFch|ryP MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HMV-II NGLMb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mwNmlEPTB;MUSuNlMxQSEQvF2= M{GzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
BEN NGKz[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMc|lKSzVyPUGzMlEzPjRizszN MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NBsusSR NFW3OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3hW4JKSzVyPUGwMlgzOzVizszN MlLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MS-1 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnpe4RKSzVyPUGwMlgzOzVizszN MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
BFTC-905 NYPkN2YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TvSWlEPTB;MUCuNVI{OyEQvF2= MkHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1 NH;pdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KwN2lEPTB;OT6wOlc{QSEQvF2= MljVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MPP-89 NFPkfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fwTWlEPTB;OD60OlI2OSEQvF2= NUfITlBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
T-24 NHXafIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom0TWM2OD16LkSwOlc{KM7:TR?= NF;aUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KP-N-YN NFHhcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jYOmlEPTB;OD6yNFE6KM7:TR?= NE\3R|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
IST-MES1 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXZSWFKSzVyPUeuPVU3OzdizszN NEXNbYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H358 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHJTWM2OD15LkWzPEDPxE1? NEXnc209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
GOTO NHfaSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7hVlBUUUN3ME22MlM6OTZzIN88US=> NGHOXHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
DU-145 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flNWlEPTB;Mz65N|gyOSEQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
EoL-1-cell NIPoOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17wVmlEPTB;MD6zOFc3OyEQvF2= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KYSE-270 M{ixdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\XfI1KSzVyPUK0MlU2PzNizszN NHf2NYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HCC1806 NF[yXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj3TWM2OD1{ND63O|k6KM7:TR?= MnTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HuO-3N1 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrvO5VKSzVyPUK1MlgyQDVizszN NFjmWmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HOS NVTJUI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD1{NT65NlkzKM7:TR?= M4XUW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
KYSE-510 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\xTW97UUN3ME2yOk4yPjF{IN88US=> MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
COLO-741 M{\Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXTTWM2OD1{Nj6zN|I6KM7:TR?= M{TvNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
H-EMC-SS M1T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfFe217UUN3ME2yOk46OjR3IN88US=> NEL5XoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HCC1937 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ5LkKyN|gh|ryP MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H2126 NIm2OldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HETmlEPTB;MkeuN|k4PSEQvF2= NXex[ZRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H1703 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHwTWM2OD1{OD6wOFE{KM7:TR?= MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
U-2-OS M3v1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LvR2lEPTB;MkiuOVUyPSEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DBTRG-05MG MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXOTWM2OD1{OD61OlUyKM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
MHH-ES-1 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNzLkm0NUDPxE1? NYTNTIF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1419 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H4XmlEPTB;M{KuNVEyQSEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HOP-62 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\UXFNKSzVyPUOyMlI4ODFizszN NXjYfWN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
AM-38 M2\5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN{Lkm5N|Eh|ryP NFnDbFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H2009 NFjQWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTYTWM2OD1|Mz60NFA4KM7:TR?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
EM-2 NYnnPWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD1|Mz61OVEyKM7:TR?= NH;mWZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
SW1116 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHjV5M1UUN3ME2zOE41QDN6IN88US=> NX3PR5U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
SK-N-AS M2\lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXOTWM2OD1|NT6wO|E1KM7:TR?= NF7nSpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
ChaGo-K-1 NFLNPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nvVmlEPTB;M{WuOlA{OiEQvF2= NWXhSWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
RT-112 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG0TWM2OD1|NT65PFc6KM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HTC-C3 M121dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrZcoJKSzVyPUO2MlI{PTVizszN MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
SK-NEP-1 NHfzTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGwfXd{UUN3ME2zOk43OTB4IN88US=> Mnj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
LB831-BLC NGrz[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN5Lk[1OFEh|ryP M1TmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
CTB-1 NIG4VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WWplKSzVyPUO4MlQ2OTJizszN NF[wTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
MOLT-4 M3Ow[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTnTWM2OD1|OD64N|kyKM7:TR?= M4\xZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SW756 NGPz[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4fY9uUUN3ME20NE46Ozh3IN88US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
CAL-72 NV3LRXpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn2TWM2OD12Mj6wN{DPxE1? NFyyZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KNS-62 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnuTWM2OD12Mj62Nlk3KM7:TR?= M2nhS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
KARPAS-299 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR|LkOyN|Mh|ryP NGq4ZY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HEL NGX1ZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR3LkS2OFYh|ryP NUPXVnFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KP-4 M3XqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzyTWM2OD12Nj63N|YyKM7:TR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NEC8 NITSc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjsTWM2OD12Nz6xOlYyKM7:TR?= MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
G-402 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LZVGlEPTB;NEiuO|AyOiEQvF2= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
Sf21 NIXhNYRHfW6ldHnvckBie3OjeR?= M{DiVWJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKGi3bXHuJIJqd3SrbjDsZYJmdGynZDDwN|gh[WyyaHGgLFkhfG9iM{WyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[yNUBqdnOnY4SgZ4VtdHNiU2DSJIFv[Wy7c3nzMEBM\CB;IECuNFAxOTJ|IN88UU4> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|NESzNUc,Ojh6M{S0N|E9N2F-
THP1 NHzvb|BHfW6ldHnvckBie3OjeR?= NXT2NpJrUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxN{DPxE1w NEDSRY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
U937 NVPObpZvSW62aXnu[oxidW2jdH;yfUBie3OjeR?= MWWyJIhzew>? M1K4emFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4h\GmoZnXy[Y51cWG2ZXSgbJVu[W5iVUmzO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBNWFNvc4TpcZVt[XSrb36g[o9zKDRiaILzJIJ6KHOjbnT3bYNpKEWOSWPBJJJmdGG2aY\lJJRwKH[naHnjcIUufHKnYYTl[EBkd262cn;sMEBKSzVyIE2gNE4xOTVizszNMi=> M4T5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OECwN|A6Lz5{NkiwNFMxQTxxYU6=
THP1 M3jN[2Z2dmO2aX;uJIF{e2G7 M{i1T2lvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBVUFBzIHPlcIx{NCCLQ{WwJF0hOC5yMUig{txONg>? M2rFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{W2PVI6Lz5zOUO1OlkzQTxxYU6=
THP1 M1zMRWZ2dmO2aX;uJIF{e2G7 NHzZeplKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJJR2dW:{IH7lZ5Jwe2m|IH\hZ5Rwei2jbIDoZUApXE6ILXHsdIhiMSCycn;keYN1cW:wIHnuJHRJWC1zIHPlcIx{NCCHQ{WwJF0hOC5yMUig{txONg>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB6NkS4OUc,OTJyOE[0PFU9N2F-
THP NIn0[YtHfW6ldHnvckBie3OjeR?= M373[3Rme3SnZDDmc5IhcW6qaXLpeIlwdiCxZjDUeY1weiCwZXPyc5NqeyCoYXP0c5ItKGGucHjhJIlvKFSKUDDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5? M1jVPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NU[xNFg4Lz5zNEW2NVA5PzxxYU6=
THP1 NVO4RlFZTnWwY4Tpc44h[XO|YYm= M{LtdWlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBqdiCWSGCxJINmdGy|LDDJR|UxKD1iMD6wNVgh|ryPLh?= NXTNb3VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlAyODhpPkG3OVYxOTB6PD;hQi=>
THP1 NYXh[4F6TnWwY4Tpc44h[XO|YYm= NXr2eG9HUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlAyQCEQvF2u M1zuSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[yPVQxLz5zOES2Nlk1ODxxYU6=
HLF NGXZN3dHfW6ldHnvckBie3OjeR?= MnrDTY5pcWKrdHnvckBw\iCyM{jhcJBp[SCyaH;zdIhwenmuYYTpc44hcW5iSVytNU1idHCqYT3zeIlufWyjdHXkJGhNTiClZXzsd{whUUN3MDC9JFAvODR5IN88UU4> NVXod5VWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NFIzPjJpPkG4OlAzOjZ{PD;hQi=>
HLF NX25V4VETnWwY4Tpc44h[XO|YYm= NHnQVJBKdmirYnn0bY9vKG:oIFjTVFI4KHCqb4PwbI9zgWyjdHnvckBqdiCLTD2xMYFteGijLYP0bY12dGG2ZXSgTGxHKGOnbHzzMEBKSzVyIE2gNE4xPThizszNMi=> MnvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4MEKyOlIoRjF6NkCyNlYzRC:jPh?=
HEK293F MUfGeY5kfGmxbjDhd5NigQ>? NYHGZ2hpUW6qaXLpeIlwdiCxZjDzc4RqfW1iYYLz[Y5ifGViYXP0bZZifGWmIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBDenWpaXGgcYFt[XmrIF3QT|Eh\XiycnXzd4VlKGmwIFjFT|I6O0ZiY3XscJMhfXOrbnegSmFONXB|OITp[IUh[XNic4Xid5Rz[XSnIHL5JGlOSVBiYYPzZZktKEmFNUCgQUAxNjF2IN88UU4> MnXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzOlIoRjJ7NUSxN|YzRC:jPh?=
BL21(DE3) MWDGeY5kfGmxbjDhd5NigQ>? NGDkZ2lKdmirYnn0bY9vKG:oIICzPIFteGijIHHjeIl3\SCob4LtJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCKVGLGJIF{e2G7LDDJR|UxKD1iMD6yOUDPxE1w MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Mki4OVgoRjF7OUK4PFU5RC:jPh?=
whole blood cells MVfBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NVTpVVdiPCCqcoO= NX7iPWlOSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckB4cG:uZTDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHC{b3T1Z5Rqd25iYX\0[ZIhPCCqcoOgZpkhfGmvZT3y[ZNwdH[nZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlYh|ryPLh?= NFP5Zpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0PVI5Oid-MkK3OFkzQDJ:L3G+
A673 M3q3Z5FJXFNiYYPzZZk> M1L1VpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NXfpOW81eUiWUzDhd5NigQ>? NUXPSo44eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MWDxTHRUKGG|c3H5 MnLFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NHXqZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NHTQT|ZyUFSVIHHzd4F6 NXz6OndWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NEDYU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MYnxTHRUKGG|c3H5 MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? M3W0e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NUXSPYdWeUiWUzDhd5NigQ>? NITNZXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz M{f6V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NH\1RmhyUFSVIHHzd4F6 NYW3fVNteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M3LlfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-p38 / p38 ; 

PubMed: 23349819     


The inhibitory effect of phosphorylated p38 in KB, KBV200 (B) and in MCF-7, MCF-7/ADR (C) treated with BIRB796 at various concentrations after 24 h. 

mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; 

PubMed: 26844273     


CRC cells were treated with 4 μM LY2228820, 10 μM BIRB796 or 10 μM SB202190 for 2 h and p38 and mTORC1 signaling was analyzed by immunoblot.

p-p38 / γ-H2AX ; 

PubMed: 27082306     


The expression of p-P38 was tested via protein gel blot after the cells were treated with BIRB796.

23349819 26844273 27082306
体内研究 BIRB 796按30 mg/kg剂量作用于LPS刺激的鼠,抑制TNF-α达84%。作用于患胶原诱导的关节炎鼠显示高效性。[1] BIRB 796口服处理给鼠,具有好的药物动力学特征。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:

[2]

- 合并
  • Animal Models: 患胶原诱导的关节炎雌性Balb/c鼠
  • Dosages: 1 mg/kg(静脉注射)或10 mg/kg(口服)
  • Administration: 静脉注射或口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (189.51 mM)
Ethanol 100 mg/mL (189.51 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 527.66
化学式

C31H37N5O3

CAS号 285983-48-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02211885 Completed Drug: 14C-BIRB 796 BS Healthy Boehringer Ingelheim October 2002 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品

Tags: 购买Doramapimod (BIRB 796) | Doramapimod (BIRB 796)供应商 | 采购Doramapimod (BIRB 796) | Doramapimod (BIRB 796)价格 | Doramapimod (BIRB 796)生产 | 订购Doramapimod (BIRB 796) | Doramapimod (BIRB 796)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID